This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Europe
10 - 12 June, 2025
Congress CenterBasel Switzerland

Sara Mangsbo, PhD
Professor at Uppsala University
Speaker

Profile

Sara Mangsbo, Professor Uppsala University and CSO/founder of Immuneed AB. Sara defended her thesis in 2010 around local immune modulation of bladder cancer and continued with a postdoctoral period in Professor Melief and Professor Ossendorp’s laboratory at LUMC in the Netherlands. The project involved how to use long peptide vaccines in an immune complex formulation to enhance antigen delivery into dendritic cells.

She has continued the work in Sweden in collaboration with Associate professor Drijfhout and taken the project into a preclinical drug development project. She is also active in the antibody therapy field with antibodies targeting CD40 and checkpoint blockers. She has been part in the preclinical development project of ADC1013 that is now in clinical trial, an antibody that was licensed to JnJ in 2015.

Agenda Sessions

  • Enhancing Neoantigen Peptide Delivery with Affinity-Based CD40 Targeting Antibody Conjugates

    11:20